13results about "Mucins" patented technology

The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

Provided herein are compositions, methods, and uses relating to antibodies that immunospecifically bind to glycosylated forms of MUC16, a tethered mucin. Also provided herein are uses and methods for managing, treating, or preventing a disease, e.g., cancer.

The present disclosure relates to chimeric Tim receptors, host cells modified to contain chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

Described herein are synthetic glycopolypeptides that contain sugars identified as active in mucin. These compounds reduce the virulence of high-priority opportunistic pathogens, including, but not limited to, Salmonella enterica subsp. enterica serovar Typhimurium, Candida albicans, and Gardnerella vaginalis, without reducing the viability of beneficial Lactobacillus crispatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

An anti-tumor fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein may contain protein MBP and protein MUC1-N. An amino acid sequence of the fusion protein is set forth in SEO ID NO.3. The fusion protein can be used for the prevention and / or treatment of pancreatic cancer.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

Disclosed are synthetic mucins comprising homopolymers or copolymers of sugar and amino acid building blocks that mimic the structure and function of naturally-occurring mucins. Methods for their synthesis involve ring-opening polymerization of sugar-amino acid conjugate monomers, optionally together with amino acid monomers or derivatives serving as spacers or crosslinkers, followed by deprotection steps to yield tailored polymers with controlled sequence, molecular weight, and functionality. Compositions containing these synthetic mucins have utility in pharmaceutical, cosmetic, biomedical, and industrial applications such as lubricants, adhesives, moisturizers, protective coatings, and mucus substitutes.